Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Rheumatol. 2015 Dec 15;43(2):273–281. doi: 10.3899/jrheum.150179

Figure 1.

Figure 1

Relationships of anti-carbamylated protein antibody (ACarP Ab) titer to seropositivity and anti-cyclic citrullinated peptide antibody (anti-CCP). Panels (A) and (B) represent the Dartmouth established RA cohort, and panels (C) and (D) represent the Sherbrooke EUPA cohort. A, C. Log-transformed ACarP Ab is higher in seropositive than in seronegative RA patients in both the Dartmouth cohort (seronegative: n = 45, mean (SEM) = 0.66 (0.08); seropositive: n = 167, mean (SEM) = 1.23 (0.05); p<0.0001) and the Sherbrooke cohort patients (seronegative: n = 165, mean (SEM) = 0.40 (0.05); seropositive: n = 171, mean (SEM) = 0.97 (0.05); p< 0.0001). B, D. Among seropositive samples, a positive correlation is observed between ACarP Ab titer and anti-CCP in both cohorts (p< 0.0001, p= 0.01, respectively). Diagonal lines represent lines of best fit.